The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)-Global Market Insights and Sales Trends 2025
Synopsis
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size is expected to reach US$ 56720 million by 2029, growing at a CAGR of 21.4% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in various end use industries. The expanding demands from the Breast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment and Lung Cancer Diagnosis and Treatment, are propelling Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market. CellSearch, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Others segment is estimated at % CAGR for the next seven-year period.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) covered in this report include Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee and Fluxion, etc.
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, Segment by Type:
CellSearch
Others
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size is expected to reach US$ 56720 million by 2029, growing at a CAGR of 21.4% from 2023 to 2029. The market is mainly driven by the significant applications of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in various end use industries. The expanding demands from the Breast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment and Lung Cancer Diagnosis and Treatment, are propelling Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market. CellSearch, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Others segment is estimated at % CAGR for the next seven-year period.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) covered in this report include Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee and Fluxion, etc.
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, Segment by Type:
CellSearch
Others
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)
1.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Overview
1.1.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Scope
1.1.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Status and Outlook
1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2018-2029)
1.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Region (2018-2023)
1.5 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
1.6.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
1.6.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
1.6.3 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
1.6.4 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
1.6.5 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2018-2029)
2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Type
2.1 Introduction
2.1.1 CellSearch
2.1.2 Others
2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Type (2018-2023)
2.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Type (2018-2029)
3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Overview by Application
3.1 Introduction
3.1.1 Breast Cancer Diagnosis and Treatment
3.1.2 Prostate Cancer Diagnosis and Treatment
3.1.3 Colorectal Cancer Diagnosis and Treatment
3.1.4 Lung Cancer Diagnosis and Treatment
3.1.5 Other Cancers Diagnosis and Treatment
3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Application (2018-2023)
3.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Breakdown by Application (2018-2029)
4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Competition Analysis by Players
4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) as of 2022)
4.3 Date of Key Players Enter into Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market
4.4 Global Top Players Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Headquarters and Area Served
4.5 Key Players Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Solution and Service
4.6 Competitive Status
4.6.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Janssen
5.1.1 Janssen Profile
5.1.2 Janssen Main Business
5.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.1.4 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.1.5 Janssen Recent Developments
5.2 Qiagen
5.2.1 Qiagen Profile
5.2.2 Qiagen Main Business
5.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.2.4 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.2.5 Qiagen Recent Developments
5.3 Advanced Cell Diagnostics
5.3.1 Advanced Cell Diagnostics Profile
5.3.2 Advanced Cell Diagnostics Main Business
5.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.3.4 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.3.5 ApoCell Recent Developments
5.4 ApoCell
5.4.1 ApoCell Profile
5.4.2 ApoCell Main Business
5.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.4.4 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.4.5 ApoCell Recent Developments
5.5 Biofluidica
5.5.1 Biofluidica Profile
5.5.2 Biofluidica Main Business
5.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.5.4 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.5.5 Biofluidica Recent Developments
5.6 Clearbridge Biomedics
5.6.1 Clearbridge Biomedics Profile
5.6.2 Clearbridge Biomedics Main Business
5.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.6.4 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.6.5 Clearbridge Biomedics Recent Developments
5.7 CytoTrack
5.7.1 CytoTrack Profile
5.7.2 CytoTrack Main Business
5.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.7.4 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.7.5 CytoTrack Recent Developments
5.8 Celsee
5.8.1 Celsee Profile
5.8.2 Celsee Main Business
5.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.8.4 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.8.5 Celsee Recent Developments
5.9 Fluxion
5.9.1 Fluxion Profile
5.9.2 Fluxion Main Business
5.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.9.4 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.9.5 Fluxion Recent Developments
5.10 Gilupi
5.10.1 Gilupi Profile
5.10.2 Gilupi Main Business
5.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.10.4 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.10.5 Gilupi Recent Developments
5.11 Cynvenio
5.11.1 Cynvenio Profile
5.11.2 Cynvenio Main Business
5.11.3 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.11.4 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.11.5 Cynvenio Recent Developments
5.12 On-chip
5.12.1 On-chip Profile
5.12.2 On-chip Main Business
5.12.3 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.12.4 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.12.5 On-chip Recent Developments
5.13 YZY Bio
5.13.1 YZY Bio Profile
5.13.2 YZY Bio Main Business
5.13.3 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.13.4 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.13.5 YZY Bio Recent Developments
5.14 BioView
5.14.1 BioView Profile
5.14.2 BioView Main Business
5.14.3 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.14.4 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.14.5 BioView Recent Developments
5.15 Fluidigm
5.15.1 Fluidigm Profile
5.15.2 Fluidigm Main Business
5.15.3 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.15.4 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.15.5 Fluidigm Recent Developments
5.16 Ikonisys
5.16.1 Ikonisys Profile
5.16.2 Ikonisys Main Business
5.16.3 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.16.4 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.16.5 Ikonisys Recent Developments
5.17 AdnaGen
5.17.1 AdnaGen Profile
5.17.2 AdnaGen Main Business
5.17.3 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.17.4 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.17.5 AdnaGen Recent Developments
5.18 IVDiagnostics
5.18.1 IVDiagnostics Profile
5.18.2 IVDiagnostics Main Business
5.18.3 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.18.4 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.18.5 IVDiagnostics Recent Developments
5.19 Miltenyi Biotec
5.19.1 Miltenyi Biotec Profile
5.19.2 Miltenyi Biotec Main Business
5.19.3 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.19.4 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.19.5 Miltenyi Biotec Recent Developments
5.20 ScreenCell
5.20.1 ScreenCell Profile
5.20.2 ScreenCell Main Business
5.20.3 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.20.4 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.20.5 ScreenCell Recent Developments
5.21 Silicon Biosystems
5.21.1 Silicon Biosystems Profile
5.21.2 Silicon Biosystems Main Business
5.21.3 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Products, Services and Solutions
5.21.4 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (US$ Million) & (2018-2023)
5.21.5 Silicon Biosystems Recent Developments
6 North America
6.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Dynamics
11.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
11.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers
11.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
11.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
